在初级PCI中用于ST段升高心肌梗塞和大血栓负担的冠心内低剂量重组组织等离子体激活剂:随机试验
Shamir R Mehta1, Natalia Pinilla-Echeverri1, Denise Tiong2
1Population Health Research Institute, Hamilton, ON, Canada; McMaster University, Hamilton, ON, Canada; Hamilton Health Sciences, Hamilton, ON, Canada.
Journal of the American College of Cardiology
|November 6, 2025
概括
在接受初级穿皮冠状动脉干预 (PCI) 的ST升高心肌梗塞 (STEMI) 患者中,冠状动脉内高血压剂没有减少微血管阻塞或主要不良心血管事件 (MACE). 这些发现不支持在接受初级PCI的STEMI患者中常规使用这种疗法.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 血栓溶解疗法 血栓溶解疗法
背景情况:
- 对于ST升高心肌梗塞 (STEMI) 患者进行初级皮肤穿冠状动脉干预 (PCI),导致微血管阻塞,对血栓的远端栓塞是常见的.
- 低剂量重组组织等离子体激活剂 (alteplase) 的冠状动脉内输送是改善微血管阻塞的潜在策略,而不会增加全身出血风险.
研究的目的:
- 评估辅助性冠状管内阿尔特等激素在减少小血管阻塞和主要心血管不良事件 (MACE) 的疗效,在接受初级PCI的高血栓负担的STEMI患者中.
主要方法:
- 一个多中心的,随机的,双盲试验在STEMI患者中进行,这些患者患有高血栓负担,接受初级PCI.
- 患者在再输血后直接注入心脏病相关动脉内冠状动脉中 (10毫克或20毫克) 或安慰剂.
- 主要结局包括MACE,心肌红色度 (MBG) 0/1,远端栓塞,或在PCI后30分钟未能达到≥50%的ST段分辨率.
主要成果:
- 主要结局发生在53.3%的组合阿尔特等组患者中,而安慰剂组的52.9% (相对风险1.00,P>0.99).
- 在阿尔特普拉斯和安慰剂组之间,在主要结局的任何组成部分中都没有观察到显著差异.
- 一名患者在阿尔特普拉斯20毫克组中经历了严重出血;在阿尔特普拉斯组中发现了更多心室动的趋势.
结论:
- 在接受初级PCI的STEMI患者的复合初级结局方面,静脉内高位素的使用并不优于安慰剂.
- 研究数据不支持在接受初级PCI的STEMI患者中常规使用冠心内阿尔泰.
相关概念视频
01:30Acute Coronary Syndrome I: Introduction
753
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
753
01:28Acute Coronary Syndrome IV: Interprofessional Care
205
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
205
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
293
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
293
01:30Acute Coronary Syndrome III: Diagnostic Studies
200
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
200
01:27Peripheral Artery Disease III: Interprofessional Care
231
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
231
01:27Coronary Artery Disease V: Interprofessional Care
207
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
207